Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.
Start | Author Index

332.P1.39 Antithrombotic Therapy Poster I

Saturday, December 6, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
980
An Adaptive-Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Thromboprophylaxis after Total Knee Replacement Surgery

Alexander T Cohen, MBBS, MSc, MD, FRACP1*, Donald Armstrong, BSc., MD, FRCSC2*, Tadeusz Gazdzik, MD3*, Camilla Ryge, MD, PhD4*, Raphael Pak, PhD5, Jaap Mandema, PhD6*, Rebecca Boyd, PhD7*, Scott McBride, MA8* and Lorenzo A. DiCarlo, MD5

1Department of Vascular Surgery, King's College Hospital, London, United Kingdom
2Guelph General Hospital, Guelph, ON, Canada
3Kliniczny Oddzial Chirurgii Urazowo-Ortopedycznej, Sosnowiec, Poland
4Horsholm Hospital, Horsholm, Denmark
5Pfizer Global R & D, Ann Arbor, MI
6Quantitative Solutions Inc, Menlo Park, CA
7Pfizer Global R & D, New London, CT
8United BioSource Corporation, Ann Arbor, MI
981
Efficacy and Safety Profile of Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Moderately Renally Impaired Patients after Total Knee or Hip Replacement SurgeryClinically Relevant Abstract

Ola E Dahl1*, Andreas A Kurth2*, Nadia Rosencher3*, Janet Schnee4*, Andreas Clemens4*, Herbert Noack4* and Bengt I Eriksson5*

1Thrombosis Research Institute, London, United Kingdom
2Orthopaedic University Hospital Stiftung Friedrichsheim, Frankfurt, Germany
3Paris 5 University, Paris, France
4Boehringer Ingelheim, Ingelheim, Germany
5Sahlgrenska University Hospital / Östra, Gothenburg, Sweden
982
CYP2C19*2 and *3 Polymorphisms Are Associated with High Post-Treatment Platelet Reactivity in Korean Patients with Acute Coronary Syndrome Undergoing Percutanous Coronary Intervention

In-Suk Kim, PhD, MD.1, Young-Hoon Jeong2* and Gyeong-Won Lee3*

1Laboratory Medicine, Gyeong-Sang Natl. Univ. Hosp., Jinju, South Korea
2Internal medicine, Gyeong-sang national university hospital, Jinju, South Korea
3Internal medicine, Gyeong-Sang Natl. Univ. Hosp., Jinju, South Korea
983
Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors

Genmin Lu, PhD*, Francis R. DeGuzman*, Sanjay Lakhotia, PhD*, Stanley J Hollenbach*, David R Phillips, PhD and Uma Sinha, PhD

Portola Pharmaceuticals Inc, South San Francisco, CA
984
Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey Clinically Relevant Abstract

Ajay K Kakkar, Prof., PhD1, Alexander T Cohen, MBBS, MSc, MD, FRACP2*, Victor F Tapson, MD3*, Jean-Francois Bergmann, Prof., MD4*, Samuel Z. Goldhaber, Prof., MD5 and Frederick A Anderson Jr., PhD6

1Barts and The London School of Medicine, London, United Kingdom
2Department of Vascular Surgery, King's College Hospital, London, United Kingdom
3Duke University Medical Center, Durham, NC
4Hôpital Lariboisiere, University Paris, Paris, France
5Brigham & Women's Hospital, Boston, MA
6Center for Outcomes Research, Univ. of Mass. Medical School, Worcester, MA
985
Residual Vein Thrombosis for Assessing the Optimal Management of Deep Vein Thrombosis in Cancer Patients: An Interim Analysis of the Cancer DACUS Study 

Sergio Siragusa, MD

Istituto di Ematologia, Policlinico Universitario di Palermo, Palermo, Italy
986
Antithrombin Alfa in Hereditary Antithrombin Deficient Patients at High Risk for Thromboembolic Complications

Robert Campbell Tait1* and Johan TM Frieling2*

1Haematology, Royal Infirmary, Glasgow, United Kingdom
2Pharmasquire Consultancy B.V., Netherlands
987
Early Minor Bleeding as Risk Indicator for Major Bleeding in Patients Using Vitamin-K-Antagonists, Independent of Quality of AnticoagulationClinically Relevant Abstract

Nic J.G.M. Veeger1*, Margriet Piersma-Wichers2*, Hans L. Hillege3* and Jan van der Meer1*

1Division of Haemostasis, Thrombosis and Rheology, University Medical Center Groningen, Groningen, Netherlands
2Trombosis Service Groningen, Groningen, Netherlands
3Trial Coordination Center, University Medical Center Groningen, Groningen, Netherlands
988
Use of Pharmacogenetic Factors to Predict Warfarin Dose in Children - a Retrospective Cohort Study

Emma Jones, MD1, Mary Bauman, RN, BA2*, M. Patricia Massicotte, MD2*, Brian Gage, MD3*, Ebony Courtney, MA4* and Lisa Bomgaars, MD1

1Texas Children's Cancer Center & Hematology Service, Houston, TX
2Stollery Children's Hospital, Edmonton, AB, Canada
3Washington University Medical School, St. Louis, MO
4Division of Molecular Pathology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX
989
Adjunctive Catheter-Directed Venous Thrombolysis in Iliofemoral Deep Vein Thrombosis; Short-Term Results from the CaVenT Study, a Multicenter Randomized Controlled Trial

Tone Rønnaug Enden, MD1*, Carl-Erik Slagsvold, MD, PhD2*, Nils-Einar Kløw, MD, PhD1* and Per Morten Sandset, MD, PhD3

1Departments of Radiology, Ullevål University Hospital, N-0407 Oslo, Norway
2Department of Vascular Diagnosis and Research, Aker University Hospital, N-0514 Oslo, Norway
3Dept. of Hematology, Ullevaal University Hospital, Oslo, Norway
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>

*signifies non-member of ASH